Open access
Aug 2026
Evaluating global clinical trials and development trends of antibody-drug conjugates
Antibody-drug conjugates (ADCs) represent a breakthrough in tumor-targeted therapy, showing promise in both solid tumors and hematological malignancies. By 1 September 2025, more than 370 ADC candidates had entered clinical development, 17 unique products had received at least one regulatory approval worldwide, and mor...
Jin-Tao Hu, Cong Lai, Jun-Jie Wang et al.
· Biomarker Research · 0 citations